FDA 483 - InBios International, Inc. - June 16, 2022

An FDA inspection of InBios International, Inc. in Seattle, WA, revealed four observations related to deficiencies in their quality system. Issues included inadequate procedures for environmental condition control, supplier qualification, and customer complaint handling. Additionally, the firm's sampling plans for raw materials were found not to be based on valid statistical rationale.